Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | PDE2A | O00408 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3753277 | 0.86 | MAPK1 (0.47) | ALDH1A1KDM4ELMNACYP1A2MAPK1 | |
| SCHEMBL9191087 | 0.83 | TDP1 (0.68) | ALDH1A1KDM4ELMNATDP1CYP1A2 | |
| SCHEMBL25136509 | 0.83 | LMNA (0.49) | ALDH1A1KDM4ELMNATDP1CYP1A2 | |
| SCHEMBL2897680 | 0.81 | LMNA (0.71) | ALDH1A1KDM4ELMNATDP1CYP1A2 | |
| SCHEMBL13728897 | 0.81 | MAPT (0.43) | ALDH1A1KDM4ELMNACYP1A2L3MBTL1 | |
| SCHEMBL18075579 | 0.81 | POLB (0.51) | ALDH1A1KDM4ELMNATDP1CYP1A2 | |
| SCHEMBL4826028 | 0.81 | KDM4E (0.50) | ALDH1A1KDM4ELMNAKMT2AL3MBTL1 | |
| SCHEMBL4038668 | 0.80 | ALDH1A1 (0.55) | ALDH1A1KDM4ELMNATDP1CYP1A2 | |
| SCHEMBL1760242 | 0.80 | ALDH1A1 (0.55) | ALDH1A1KDM4ELMNATDP1CYP1A2 | |
| SCHEMBL3711489 | 0.80 | ALDH1A1 (0.55) | ALDH1A1KDM4ELMNATDP1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4143179-B1 | AZETIDIN-3-YLMETHANOL DERIVATIVES AS CCR6 RECEPTOR MODULATORS FOR THE TREATMENT OF CANCER | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-10-22 | — | — | EP | disclosed |
| US-20230174514-A1 | AZETIDIN-3-YLMETHANOL DERIVATIVES AS CCR6 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-06-08 | — | — | US | disclosed |
| EP-4143179-A1 | AZETIDIN-3-YLMETHANOL DERIVATIVES AS CCR6 RECEPTOR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2023-03-08 | — | — | EP | disclosed |
| EP-3270926-B1 | TRIAZOLYL PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME (US) | 2021-08-04 | — | — | EP | disclosed |
| EP-3291817-B1 | HETEROARYL-PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME (US) | 2019-10-02 | — | — | EP | disclosed |
| US-10358435-B2 | Triazolyl pyrimidinone compounds as PDE2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-07-23 | — | — | US | disclosed |
| US-10195201-B2 | Heteroaryl-pyrimidinone compounds as PDE2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20180280390-A1 | Heteroaryl-Pyrimidinone Compounds as PDE2 Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-10-04 | — | — | US | disclosed |
| US-20180237422-A1 | TRIAZOLYL PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-08-23 | — | — | US | disclosed |
| EP-3291817-A1 | HETEROARYL-PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2018-03-14 | — | — | EP | disclosed |
| EP-3270926-A1 | TRIAZOLYL PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2018-01-24 | — | — | EP | disclosed |
| WO-2016179059-A1 | HETEROARYL-PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-11-10 | — | — | WO | disclosed |
| WO-2016149058-A1 | TRIAZOLYL PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-09-22 | — | — | WO | disclosed |
| US-20110152235-A1 | Aminopyrimidine Kinase Inhibitors | Jasco Pharmaceuticals, LLC (US) | 2011-06-23 | — | — | US | disclosed |
| US-5324710-A | Sulfonated heterocyclic carboxamides and their use as herbicides, and growth regulators | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180280390-A1 | Heteroaryl-Pyrimidinone Compounds as PDE2 Inhibitors | PDE2A, PDE12, PDE7B | ALDH1A1 718/4885KDM4E 2517/4885LMNA 4612/4885 |
| US-20180237422-A1 | TRIAZOLYL PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | PDE2A, PDE12, PDE4D | ALDH1A1 608/4885KDM4E 2467/4885LMNA 4687/4885 |
| US-10358435-B2 | Triazolyl pyrimidinone compounds as PDE2 inhibitors | PDE2A, PDE12, PDE4D | ALDH1A1 608/4885KDM4E 2467/4885LMNA 4687/4885 |
| US-10195201-B2 | Heteroaryl-pyrimidinone compounds as PDE2 inhibitors | PDE2A, PDE12, PDE7B | ALDH1A1 718/4885KDM4E 2517/4885LMNA 4612/4885 |
| US-20110152235-A1 | Aminopyrimidine Kinase Inhibitors | PIM1, PIM2, PIM3 | ALDH1A1 3532/4885KDM4E 1225/4885LMNA 3865/4885 |
| US-20230174514-A1 | AZETIDIN-3-YLMETHANOL DERIVATIVES AS CCR6 RECEPTOR MODULATORS | CCR6, CCR1, CCR3 | ALDH1A1 1097/4885KDM4E 3444/4885LMNA 4580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.